Condition
Lupus Nephritis - WHO Class III
Total Trials
4
Recruiting
1
Active
3
Completed
0
Key Insights
Highlights
No notable highlights available yet
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 0 completed with results
Key Signals
Data Visualizations
Phase Distribution
4Total
Early P 1 (1)
P 1 (2)
P 2 (1)
Trial Status
Active Not Recruiting2
Not Yet Recruiting1
Recruiting1
Clinical Trials (4)
Showing 4 of 4 trials
NCT07570862Phase 2Not Yet Recruiting
A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis
NCT06265220Phase 1Active Not RecruitingPrimary
AB-101 in Combination With B-Cell Depleting mAb in Patients Who Failed Treatment for Class III or IV Lupus Nephritis or Other Forms of Refractory Systemic Lupus Erythematosus
NCT07107659Early Phase 1Recruiting
Safety and Efficacy of ONT01 in Lupus
NCT06342960Phase 1Active Not Recruiting
KYSA-3: A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects With Refractory Lupus Nephritis
Showing all 4 trials